Cell adhesion and cancer: is there a potential for therapeutic intervention?

Bibliography

• APLIN AE, HOWE AK, JULIANO RL: Cell adhesion molecules, signal transduction and cell growth. Curr. Opin. Cell Biol. (1999) 11(6):737-744.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI H, BOELTE KC, LIN PC: Endothelial cell adhesion molecules and cancer progression Curr. Med. Chem. (2007) 14(4):377-386.
   PubMed Web of Science ®Google Scholar
• CAVALLARO U, CHRISTOFORI G: Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat. Rev. Cancer (2004) 4(2):118-132.
   PubMed Web of Science ®Google Scholar
• BERX G, VAN ROY F: The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res. (2001) 3(5):289-293.
   PubMed Web of Science ®Google Scholar
• WILLIAMS E, WILLIAMS G, GOUR BJ, BLASCHUK OW, DOHERTY P: A novel family of cyclic peptide antagonists suggests that N-cadherin specificity is determined by amino acids that flank the HAV motif. J. Biol. Chem. (2000) 275(6):4007-4012.
   PubMed Web of Science ®Google Scholar
• GREEN SK, FRANCIA G, ISIDORO C, KERBEL RS: Anti-adhesive antibodies targeting E-cadherin sensitizes multicellular tumor spheroids to chemotherapy in vitro. Mol. Cancer Ther. (2004) 3(2):149-159.
   PubMedGoogle Scholar
• OIAN X, KAROVA T, SHEPPARD AM MCNALLY J, LOWY DR: E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J. (2004) 23(8):1739-1784.
   Google Scholar
• DANEN EH: Integrins: regulators of tissue function and cancer progression. Curr. Pharm. Des. (2005) 11(7):881-891.
   PubMed Web of Science ®Google Scholar
• HOOD JD, CHERESH DA: Role of integrins in cell invasion and migration. Nat. Rev. Cancer (2002) 2(2):91-100.
   PubMed Web of Science ®Google Scholar
• KIM J, HONG SY, PARK HS, KIM DS, LEE W: Structure and function of RGD peptides derived from disintegrin proteins. Mol. Cell (2005) 19(2):205-211.
   Google Scholar
• CHUNG KH, KIM SH, HAN KY et al.: Inhibitory effect of salmosin, a Korean snake venom-derived disintegrin, on the integrin αv-mediated proliferation of SK-Mel-2 human melanoma cells. J. Pharm. Pharmacol. (2003) 55(11):1577-1582.
   Google Scholar
• SCHMITMEIER S, MARKLAND FS, RITTER MR, SAWCER DE, CHEN TC: Functional effect of contortrostatin, a snake venom disintegrin, on human glioma cell invasion in vitro. Cell. Commun. Adhes. (2003) 10(1):1-16.
   PubMed Web of Science ®Google Scholar
• OLSON DL, BURKLY LC, LEONE DR, DOLINSKI BM, LOBB RR: Anti-α4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model. Mol. Cancer Ther. (2005) 4(1):91-99.
   PubMed Web of Science ®Google Scholar
• MARCINKIEWICZ C, WEINREB PH, CALVETE JJ et al.: Obtustatin: a potent selective inhibitor of α1β1 integrin in vitro and angiogenesis in vivo. Cancer Res. (2003) 63(9):2020-2023.
   PubMed Web of Science ®Google Scholar
• CALVETE JJ, MORENO-MURCIANO MP, THEAKSTON, RD KISIEL DG, MARCINKIEWICZ: Snake venom disintegrins: novel dimeric disintegrins and structural diversification by disulphide bond engineering. Biochem. J. (2003) 372(3):725-734.
   PubMed Web of Science ®Google Scholar
• DE VISSER KE, EICHTEN A, COUSSENS LM: Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer (2006) 6(2):24-37.
   PubMed Web of Science ®Google Scholar
• MURDOCK C, LEWIS C: Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am. J. Path. (2005) 167(3):627-635.
   Google Scholar
• LEWIS CE, POLLARD JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res. (2006) 66(2):605-612.
   PubMed Web of Science ®Google Scholar
• MEIER F, SCHITTEK B, BUSCH S et al.: The Ras/Raf/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front. Biosci. (2005) 10:2986-3001.
   PubMed Web of Science ®Google Scholar
• WANG S, COLEMAN EJ, POP LM, BROOKS KJ, VITETTA ES, NIEDERKORN JY: Effect of an anti-CD54 (ICAM1) monoclonal antibody (UV3) on the growth of human uveal melanoma cells transplanted hetertopically and orthotopically in SCID mice. Int. J. Cancer (2006) 118(4):932-941.
   Google Scholar
• CAO Y: Antiangiogenic cancer therapy. Semin. Cancer Biol. (2004) 14(2):139-145.
   PubMed Web of Science ®Google Scholar
• MAZZOLINI G, OIAN C, NARVAIZA I et al.: Adenoviral gene transfer of interleukin-12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level. Hum. Gene. Ther. (2000) 11(1):113-125.
   PubMed Web of Science ®Google Scholar
• WITLOX AM, VAN BEUSECHEM VW, MOLENAAR B et al.: Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo. Clin. Cancer Res. (2004) 10(1):61-67.
   Google Scholar
• DICKERSON EB, AKTAR N, STEINBERG H et al.: Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to αvβ3 integrin. Mol. Cancer Res. (2004) 2(12):663-673.
   PubMed Web of Science ®Google Scholar
• FANI M, PSIMADAS D, ZIKOS C et al.: Comparative evaluation of linear and cyclic 99mTc-RGD peptides for targeting of integrins in tumor angiogenesis. Anti-Cancer Res. (2006) 26(1A):431-434.
   PubMed Web of Science ®Google Scholar
• SUGANO M, EGILMEZ NK, YOKOTA SJ et al.: Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res. (2000) 60(24):6942-6949.
   PubMed Web of Science ®Google Scholar
• BIBBY DC, TALMADGE JE, DALAL MK et al.: Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. Int. J. Pharm. (2005) 293(1):281-290.
   PubMed Web of Science ®Google Scholar